$XLRN ACCELERON PHARMA INC Insider Trading Week 32/2014
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ACCELERON PHARMA INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in ACCELERON PHARMA INC in week 32/2014.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 29.78 | 7,500 | 223,350 | 156,500 | 164 K to 156.5 K (-4.57 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 29.78 | 10,000 | 297,800 | 164,000 | 174 K to 164 K (-5.75 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 7,000 | 27,160 | 175,751 | |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 3,000 | 11,640 | 182,751 | |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 29.79 | 7,000 | 208,530 | 0 | 7 K to 0 (-100.00 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 7,000 | 27,160 | 7,000 | 0 to 7 K |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 29.76 | 3,000 | 89,280 | 0 | 3 K to 0 (-100.00 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 3,000 | 11,640 | 3,000 | 0 to 3 K |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.28 | 7,863 | 41,517 | 17,137 | |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.28 | 3,137 | 16,563 | 9,873 | |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 0.92 | 2,000 | 1,840 | 17,500 | |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 30.02 | 11,000 | 330,220 | 0 | 11 K to 0 (-100.00 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.28 | 7,863 | 41,517 | 11,000 | 3.1 K to 11 K (+250.65 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.28 | 3,137 | 16,563 | 3,137 | 0 to 3.1 K |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 29.79 | 2,000 | 59,580 | 0 | 2 K to 0 (-100.00 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 0.92 | 2,000 | 1,840 | 2,000 | 0 to 2 K |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.88 | 5,000 | 29,400 | 10,000 | |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 30.00 | 7,000 | 210,000 | 31,890 | 38.9 K to 31.9 K (-18.00 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.88 | 5,000 | 29,400 | 38,890 | 33.9 K to 38.9 K (+14.75 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 29.85 | 2,000 | 59,700 | 33,890 | 35.9 K to 33.9 K (-5.57 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Option Exercise | M | 5.08 | 7,500 | 38,100 | 26,250 | |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Option Exercise | M | 0.40 | 2,500 | 1,000 | 4,375 | |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 30.37 | 100 | 3,037 | 43,656 | 43.8 K to 43.7 K (-0.23 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 29.77 | 7,400 | 220,298 | 43,756 | 51.2 K to 43.8 K (-14.47 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Buy | M | 5.08 | 7,500 | 38,100 | 51,156 | 43.7 K to 51.2 K (+17.18 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 29.78 | 2,500 | 74,450 | 43,656 | 46.2 K to 43.7 K (-5.42 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Buy | M | 0.40 | 2,500 | 1,000 | 46,156 | 43.7 K to 46.2 K (+5.73 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Option Exercise | M | 1.80 | 4,316 | 7,769 | 10,496 | |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Option Exercise | M | 0.48 | 1,684 | 808 | 40,081 | |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 29.82 | 1,500 | 44,730 | 29,000 | 30.5 K to 29 K (-4.92 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 30.25 | 100 | 3,025 | 29,858 | 30 K to 29.9 K (-0.33 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 29.77 | 5,900 | 175,643 | 29,958 | 35.9 K to 30 K (-16.45 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Buy | M | 1.80 | 4,316 | 7,769 | 35,858 | 31.5 K to 35.9 K (+13.68 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Buy | M | 0.48 | 1,684 | 808 | 31,542 | 29.9 K to 31.5 K (+5.64 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Maniatis Tom | Director | Gift | G | 0.00 | 40,000 | 0 | 184,431 | 224.4 K to 184.4 K (-17.82 %) |
| Aug 13 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Option Exercise | M | 1.80 | 8,000 | 14,400 | 14,812 | |
| Aug 13 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Buy | M | 1.80 | 8,000 | 14,400 | 29,858 | 21.9 K to 29.9 K (+36.60 %) |